Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery

Biology of Blood and Marrow Transplantation

Volumn 4, Issue 2, 1998, Pages 84-92

  Shpall, Elizabeth J ^a   Champlin, Richard ^b   Glaspy, John A ^c  

^a UNIVERSITY OF COLORADO HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD34+ cells; Peripheral blood progenitor cells; Stem cell transplantation

Indexed keywords

CD34 ANTIGEN;

BLOOD; BLOOD COMPONENT THERAPY; DOSE RESPONSE; ECONOMICS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGY; LYMPHOCYTE COUNT; REVIEW;

ANTIGENS, CD34; BLOOD COMPONENT TRANSFUSION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LYMPHOCYTE COUNT;

EID: 0031608922     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.1998.v4.pm9763111     Document Type: Article

References (57)

1. Bensinger W, Singer J, Applebaum F, Lilleby K, Longin K, Rowley S, Clarke E, Clift R, Hansen J, Shields T: Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 81:3158, 1993.
2. + cells/kg predicts for hematologic engraftment. Blood 82:288a, 1993. [abstr]
3. Chabannon C, Le Corroller AG, Faucher C, Novakovitch G, Blaise D, Moatti JP, Maraninchi D, Mannoni P: Patient condition affects the collection of peripheral blood progenitors after priming with recombinant granulocyte colony-stimulating factor. J Hematother 4:171, 1995.
4. + cells reinfused is the only factor predicting both granulocyte and platelet recovery. J Hematother 5:663, 1996.
5. Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M, Wannenmacher M, Hunstein W: Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83:3787, 1994.
6. Haynes A, Hunter A, McQuaker G, Anderson S, Bienz N, Russell NH: Engraftment characteristics of peripheral blood stem cells mobilized with cyclophosphamide and the delayed addition of G-CSF. Bone Marrow Transplant 16:359, 1995.
7. + cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 19:303, 1997.
8. Morton J, Morton A, Bird R, Hutchins C, Durrant S: Predictors for optimal mobilization and subsequent engraftment of PBPCs following intermediate dose cyclophosphamide and G-CSF. Blood 86:408a, 1995. [abstr]
9. + cells in patients with breast cancer scheduled for high dose chemotherapy and peripheral blood progenitor cell support. J Hematother 6:61, 1997.
10. + cells after stem cell mobilization predict stem cell yield and posttransplant hematopoietic recovery. J Hematother 6:13, 1997.
11. + cell content predicts engraftment following allogeneic and autologous hematopoietic stem cell transplantation. Blood 84:87a, 1991. [abstr]
12. Schwartzberg L, Birch R, Blanco R, Wittlin F, Muscato J, Tauer K, Hazelton B, West W: Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 11:369, 1993.
13. Schwella N, Beyer J, Schwaner I, Heuft HG, Rick O, Hubn D, Serke S, Siegert W: Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer. J Clin Oncol 14:1114, 1996.
14. Siena S, Bregni M, Brando B, Belli N, Ravagnani F, Gandola L, Stern AC, Lansdorp PM, Bonadonna G, Gianni AM: Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 77:400, 1991.
15. Urashima M, Uchiyama H, Hoshi Y, Deguchi Y, Kamijou M, Katou Y, Fujisawa K, Akatsuka J, Maekawa K: Prediction of engraftment after peripheral blood stem cell transplantation by CD34-positive cells in grafts. Acta Paediatrica Japonica 35:325, 1993.
16. van der Wall E, Richel DJ, Holtkamp MJ, Slaper-Cortenbach IC, van der Schoot CE, Dalesio O, Nooijen WJ, Schornagel JH, Rodenhuis S: Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect on graft size. Ann Oncol 5:795, 1994.
17. Zimmerman TM, Lee WJ, Bender JG, Mick R, Williams SF: Quantitative CD34 analysis may be used to guide peripheral blood stem cell harvests. Bone Marrow Transplant 9:439, 1995.
18. Bender JG, To LB, Williams S, Schwartzberg LS: Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1:329, 1992.
19. Reiffers J, Faberes C, Boiron J, Marit G, Foures C, Ferrer AM, Cony-Makhoul P, Puntous M, Bernard P, Vezon G: Peripheral blood progenitor cell transplantation in 118 patients with hematological malignancies: analysis of factors affecting rate of engraftment. J Hematother 3:185, 1994.
20. To LB, Roberts MM, Haylock DN, Dyson PG, Branford AL, Thorp D, Ho JQ, Dart GW, Horvath N, Davy ML: Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 9:277, 1992.
21. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD: Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 71:723, 1988.
22. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HM, Link H, Zander A, Barge A: Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347:353, 1996.
23. Bensinger WI, Longin K, Applebaum F, Rowley S, Weaver C, Lilleby K, Gooley T, Lynch M, Higano T, Klarnet J: Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 87:825, 1994.
24. Bensinger W, Appelbaum F, Rowley S: Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547, 1995.
25. + cell dose and method of mobilization. Blood 84:349a, 1991. [abstr]
26. Bregni M, Siena S, Magni M, Bonadonna G, Gianni AM: Circulating hemopoietic progenitors mobilized by cancer chemotherapy and by rhGM-CSF in the treatment of high-grade non-Hodgkin's lymphoma. Leukemia 5 (Suppl 1):123, 1991.
27. + cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. J Clin Oncol 13:1922, 1995.
28. Fraser JK, Nishikubo C, Lill MC, Emmanouilides C: CD34-positive cell mobilization in patients treated with autologous stem cell transplant for Iymphoma: superior harvests in patients with primary refractory disease. Blood 88:407a, 1996. [abstr]
29. + peripheral blood stem cell (PBSC) dose influences engraftment kinetics and other relevant clinical variables. Proc ASCO 15:969a, 1996. [abstr]
30. Magalhaes-Silverman M, Kiss J, Lembersky B: Factors affecting engraftment in patients with metastatic breast cancer (MBC) treated with high dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) transplant. Proc ASCO 15:969a, 1996. [abstr]
31. + peripheral blood progenitor cells after high dose chemotherapy for patients with advanced multiple myeloma. Blood 86:390, 1995.
32. + cells in hematopoietic recovery and support measures required. Proc ASCO 15:538, 1996. [abstr]
33. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B: Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 85:588, 1995.
34. To LB, Haylock DN, Simmons PJ: The biology and clinical uses of blood stem cells. Blood 89:2233, 1997.
35. + hematopoietic stem cells. J Hematother 5:227, 1996.
36. + cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 5:213, 1996.
37. + cells predict a rapid platelet recovery after peripheral blood stem cell transplantation. Blood 85:3313, 1995.
38. -) hematopoietic progenitor mobilization following chemotherapy and/or cytokine priming. Blood 88:678a, 1996. [abstr]
39. Hohaus S, Hartmut G, Ehrhardt R, Haas R: Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exp Hematol 21:508, 1993.
40. Glaspy JA, Shpall EJ, LeMaistre CF, Briddell RA, Menchaca DM, Turner SA, Lill M, Chap L, Jones R, Wiers MD, Sheridan WP, McNiece IK: Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 90:2939, 1997.
41. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W: An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86:3961, 1995.
42. Shepherd KM, Charles P, Sage RE: Mobilization of haemopoietic stem cells by cyclophosphamide into the peripheral blood of patients with haematological malignancies. Clin Lab Haematol 13:25, 1991.
43. Neben S, Hemman S, Montgomery M, Ferrara J, Mauch P, Hellman S: Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents. Exp Hematol 21:156, 1993.
44. Tricot G, Jagannath S, Olson E: Mobilization of peripheral blood progenitor cells (PBPCs) using r-metHuSCF (SCF) and/or r-metHu-CSF (filgrastim) in heavily pretreated multiple myeloma patients. Blood 88:388a, 1996. [abstr]
45. Malachowski ME, Comenzo RL, Hillyer CD, Tiegerman KO, Berkman EM: Large-volume leukapheresis for peripheral blood stem cell collection in patients with hematologic malignancies. Transfusion 32:732, 1992.
46. Comenzo RL, Malachowski ME, Miller KB, Erban JJ, Schenkein DP, Desforges JF, Berkman EM: Engraftment with peripheral blood stem cells collected by large-volume leukapheresis for patients with lymphoma. Transfusion 32:729, 1992.
47. Comenzo RL, Malachowski ME, Miller KB, Erban JJ, Schenkein DP, Desforges JF, Berkman EM: Large-volume leukapheresis for collection of mononuclear cells for hematopoietic rescue in Hodgkin's disease. Transfusion 35:42, 1995.
48. Moskowitz CH, Stiff P, Gordon AfS, McNiece I, Ho AD, Costa JJ, Broun ER, Bayer RA, Wyres M, Hill, Jelaca-Maxwell K, Nichols CR, Brown SL, Nimer SD, Gabrilove J: Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients - results of a phase I/II trial. Blood 89:3136, 1997.
49. Weaver A, Ryder D, Crowther D, Dexter TM, Testa NG: Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem-cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. Blood 88:3323, 1996.
50. Begley CG, Basser R, Mansfield R, Thomson B, Parker WR, Layton J, To B, Cebon J, Sheridan WP, Fox RM, Green MD: Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony-stimulating factor to humans. Blood 90:3378, 1997.
51. Rasko JEJ, Basser RL, Boyd J, Mansfield R, O'Malley CJ, Hussein S, Berndt MC, Clarke K, O'Byrne J, Sheridan WP, Briggs AP, Begley CG: Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF. Br J Haematol 97:871, 1997.
52. Basser RL, Rash JEJ, Clarke CK, Cebon J, Green MD, Grigg AP, Zalcberg J, Cohen B, O'Byrne J, Menchaca DM, Fox RM, Begley CG: Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 89:3118, 1997.
53. Lebsack ME, McKenna HJ, Hoek JA, Hanna R, Feng A, Marashovsky E, Hayes FA: Safety of FLT3 ligand in healthy volunteers. Blood 90:170a, 1997. [abstr]
54. DiPersio JF, Abboud CN, Schuster MW, Winter JN, Collins DM, Santos VR, Baum CM: Phase II study of mobilization of PBSC by administration of daniplestim (SC-55494) and G-CSF in patients with breast cancer or lymphoma. Proc ASCO 16:87a, 1997. [abstr]
55. + cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 88:3223, 1996.
56. + cells in peripheral blood progenitor cell transplants (PBPCT). Blood 90 (Suppl 1):370a, 1997. [abstr]
57. Weaver CH, Birch R, Schulman KA: Effect of cell dose on resource utilization in patients undergoing transplant with peripheral blood progenitor cells. Blood 90 (Suppl 1):370a, 1997. [abstr]